.png)
.png)
.jpg "William C. Gruber, MD photo")
SVP
Pfizer
Pearl River, New York, United States
Bill is Senior Vice President of Pfizer Vaccine Clinical Research and Development, and responsible for global clinical research and development of vaccines to meet licensure and post licensure requirements. He has over 35 years of experience in vaccine development. Bill joined in 1999 as Vice President of Clinical Vaccine Research and Development for Wyeth, now Pfizer Inc. Other experience includes: Associate Professor of Pediatrics in the Division of Pediatric Infectious Diseases, Vanderbilt University School of Medicine, Director of the Diagnostic Virology Laboratory at Vanderbilt University Hospital.
Dr. Gruber’s clinical research group has been responsible for global clinical research and development of now licensed pneumococcal conjugate, meningococcal conjugate, rLP2086 meningococcal B, and influenza vaccines, as well as investigational Staph aureus, C. difficile, HIV, RSV, parainfluenza, and HSV vaccines. Dr. Gruber also guides the clinical research and development for Pfizer’s Group B streptococcus and RSV maternal immunization vaccine programs, as well as vaccines against SARS-CoV-2 (COVID-19) and Lyme disease.
He is Board certified in Pediatrics and Pediatric Infectious Diseases, Fellow of the American Academy of Pediatrics, member of the Society for Pediatric Research, Fellow of the Infectious Diseases Society of America, Fellow of the Pediatric Infectious Diseases Society, and member of the America Society for Microbiology.
Consultant/reviewer: NIAID, PATH, Bill and Melinda Gates Foundation, and scientific journals.
Education: BA, Mathematical Sciences, Rice University, Houston, Texas; MD, Baylor College of Medicine, Houston, Texas; Pediatric Residency, Chief Residency, and Pediatric Infectious Disease Fellowship, Baylor College of Medicine, and Texas Children’s Hospital, Houston, Texas.
Authorship/co-authorship on more than 200 original research articles, invited articles, and book chapters.
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Thursday, October 20, 2022
10:30 AM – 10:45 AM US ET
Thursday, October 20, 2022
2:21 PM – 2:33 PM US ET